ECG ECG
Company Profile ↓Company Overview
ECG (ECG) is a publicly traded company listed on with a market capitalization of $7.18B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 32.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 26.7%.
Net profit has compounded at 17.4% per year over the last five years.
Revenue has grown at a 11.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.75B (+31.5% YoY); net profit $201.77M.
- Trailing 12 Months Year-on-year growth — revenue +31.5%, earnings +40.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.6%, profit CAGR 17.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.55% |
| 1 Year: | 31.47% |
Compounded Profit Growth
| 5 Years: | 17.37% |
| 1 Year: | 40.68% |
Stock Price Performance
| 1 Year: | +95.49% |
| 6 Months: | +51.51% |
| 3 Months: | -16.38% |
| 1 Month: | +5.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)54.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 32.0%.
- Healthy ROCE of 26.7%.
- Compounding revenue at 11.6% over 5 years.
- Profit CAGR of 17.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 717.41M | 625.69M | 703.37M | 760.99M | 826.63M | 921.47M | 986.82M | 1.04B |
| Gross Profit | - | - | 84.91M | 74.72M | 88.58M | 89.90M | 92.49M | 119.87M | 124.22M | 130.73M |
| Operating Income | - | - | 50.09M | 38.88M | 51.31M | 53.71M | 50.98M | 72.51M | 72.38M | 77.68M |
| Net Income | 26.07M | 38.65M | 36.01M | 28.21M | 38.97M | 41.77M | 36.67M | 52.84M | 56.98M | 58.32M |
| Diluted EPS | - | - | 0.71 | 0.55 | 0.76 | 0.82 | 0.72 | 1.03 | 1.11 | 1.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 2.70B | 2.85B | 2.85B | 3.75B |
| Gross Profit | 276.05M | 321.92M | 339.45M | 454.09M |
| Operating Income | 164.64M | 190.54M | 189.91M | 264.75M |
| Net Income | 124.78M | 137.23M | 143.42M | 201.77M |
| Diluted EPS | 2.45 | 2.69 | 2.81 | 3.95 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.14B | 1.05B | 1.29B | 1.73B |
| Current Assets | - | 788.13M | 729.29M | 917.23M | 1.30B |
| Cash & Equivalents | - | 2.11M | 1.57M | 86.01M | 170.50M |
| Inventory | - | 36.84M | 42.71M | 43.75M | 45.27M |
| Receivables | - | 573.48M | 452.34M | 589.00M | 769.01M |
| Total Liabilities | - | 753.34M | 603.61M | 865.85M | 1.10B |
| Current Liabilities | - | 473.70M | 394.06M | 513.37M | 736.19M |
| Long Term Debt | - | 224.12M | 168.53M | 280.65M | 266.55M |
| Total Debt | - | 305.22M | 222.18M | 363.20M | 372.09M |
| Total Equity | 362.94M | 382.25M | 448.85M | 422.61M | 629.82M |
| Shares Outstanding | - | 51.00M | 51.00M | 50.98M | 51.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -25.50M | 171.34M | 163.38M | 156.84M |
| Investing Cash Flow | -24.57M | -19.97M | -37.06M | -56.77M |
| Financing Cash Flow | 51.50M | -151.91M | -41.87M | -15.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 10.2% | 11.3% | 11.9% | 12.1% |
| Operating Margin % | 6.1% | 6.7% | 6.7% | 7.1% |
| Net Margin % | 4.6% | 4.8% | 5.0% | 5.4% |
| ROE % | 32.6% | 30.6% | 33.9% | 32.0% |
| ROCE % | 24.9% | 28.9% | 24.5% | 26.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ECG
Everus Construction Group Inc (ECG) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Everus Construction Group Inc (ECG) posts 34% revenue growth and 53% EBITDA surge, lifting full-year outlook amid robust demand.
Everus Construction Group, Inc. (ECG) Q2 Earnings and Revenues Beat Estimates
Everus Construction Group, Inc. (ECG) delivered earnings and revenue surprises of +49.09% and +14.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?…
Everus Reports Second Quarter 2026 Results, Raises 2026 Guidance
BISMARCK, N.D., August 04, 2026--Everus Construction Group (NYSE: ECG) today reported financial results for second quarter 2026.
Everus Construction Group (ECG) Stock May Be Below Fair Value Following Its 79% Run
Everus Construction Group stock has surged over the past year, yet the Discounted Cash Flow (DCF) intrinsic value estimate now sits close to the current share price, while earnings based valuation multiples still point to the shares trading…
Everus to Acquire Epsilon Industries, Premier Off-Site Modular Construction Solutions Provider
BISMARCK, N.D., July 31, 2026--Everus Construction Group (NYSE: ECG) announced today that it has entered into a definitive agreement to acquire Epsilon Industries, a premier designer and manufacturer of complex, modular mechanical and elect…
Everus Construction Group (ECG) Strengthens from Long-Term Infrastructure Demand
Wasatch Global Investors, an asset management company, released its “Small Cap Growth Strategy” Q2 2026 investor letter. A copy of the letter can be downloaded here. Small-cap equities experienced strong gains in the second quarter, primari…
ECG — Frequently Asked Questions
What is the current share price of ECG?
As of 2026-08-05 17:25 PDT, ECG trades at $140.75 on NASDAQ/NYSE. Its 52-week range is $70.88 to $169.16.
What is the market capitalisation of ECG?
ECG has a market capitalisation of $7.18B on NASDAQ/NYSE.
What is the P/E ratio of ECG?
ECG trades at a trailing price-to-earnings (P/E) ratio of 35.63. Its price-to-book (P/B) ratio is 11.40.
What is the return on equity (ROE) of ECG?
ECG has a return on equity (ROE) of 32.04%. Its return on capital employed (ROCE) is 26.67%.
Is ECG a good stock to buy?
This page provides a data-driven analysis of ECG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.